May 9, 2025

Richard Brand
Partner
White & Case LLP
1221 Avenue of the Americas
New York, NY 10020

       Re: DYNAVAX TECHNOLOGIES CORP
           DFAN14A filed May 6, 2025
           Filed by Deep Track Technology Master Fund, Ltd. et al.
           SEC File No. 1-34207
Dear Richard Brand:

       We have reviewed your filing and have the following comments. In some of
our
comments, we may ask you to provide us with information so we may better
understand your
disclosure.

        Please respond to these comments by providing the requested information
or advise us
as soon as possible when you will respond. If you do not believe our comments
apply to your
facts and circumstances, please tell us why in your response.

       After reviewing your response to these comments, we may have additional
comments.
Defined terms have the same meaning as in your proxy materials.

DFAN14A filed May 6, 2025
General

1.     Refer to the footnotes on pages 23 and 62 of the Deep Track investor
presentation
       slide deck entitled    The Path to Creating and Preserving Value at
Dynavax.    We do
       not understand the characterization of Deep Track Nominee Donald Santel
as
          endorsed by DVAX Board.    This characterization is seemingly
inconsistent with
       statements on pages 8 and 18 of the slide deck that the Board is    dead
set against
       adding a shareholder representative as a director    and    has not
changed its position
       remaining steadfastly opposed to having a shareholder representative
join as a
       director.    Avoid this characterization in future soliciting materials,
or revise to explain
       or modify it.
2.     In various places throughout the slide deck, Deep Track makes broad and
conclusory
       assertions it attributes to    shareholders,    such as the following:
 May 9, 2025
Page 2


                Shareholders worry the Board will overpay out of desperation.
 (page 8)
                Additional to the risk and expense, shareholders are concerned
the current Board
           does not have the relevant skills or experience needed to
successfully oversee a
           vaccine development process.    (page 10)
             "Despite calls from Deep Track and other shareholders to return
excess capital,
           Dynavax is holding more excess cash as a percentage of market
capitalization
           than any other profitable midcap biotech." (page 10)

       In future soliciting materials, if similar assertions are made, include
the basis for your
       beliefs as to the views or actions of other shareholders, and provide
identifying details
       about the shareholders referenced.
3.     In future soliciting materials, ensure that citations to source
materials are provided for
       all data and other factual materials presented. These citations should
be specific
       enough to allow shareholders to find the supporting materials and should
not consist
       of generic references. See for example, the reference to "Company
Filings" in the
       footnote on page 11 of the slide deck.
        We remind you that the filing persons are responsible for the accuracy
and adequacy
of their disclosures, notwithstanding any review, comments, action or absence
of action by
the staff.

       Please direct any questions to Christina Chalk at 202-551-3263.



                                                              Sincerely,

                                                              Division of
Corporation Finance
                                                              Office of Mergers
& Acquisitions